ADHD Medications in Pregnancy & Breastfeeding
A practical, evidence-based course for clinicians making real-world ADHD pharmacotherapy decisions during pregnancy, delivery, and lactation. Five drug classes. Two clinical contexts. One decision framework.
Every chapter in this course is built to be used three ways: a 60-second bottom-line read for point-of-care decisions, a structured decision algorithm and clinic-ready toolkit for workflow integration, and a full evidence section for complex cases that need the underlying PK data, FDA label language, and special-population considerations.
Each drug class is covered in its own chapter — dextroamphetamine, methylphenidate, alpha-2 adrenergic agonists, atomoxetine, and viloxazine — followed by a cross-class synthesis chapter that integrates everything into a single decision framework. The breastfeeding section mirrors this structure, with each chapter focused on lactation pharmacokinetics, infant safety, and milk supply considerations.
-
1Executive Summary & the 60-Second Read FDA label disclosure, key teratogenicity signal, dose considerations, expert consensus — everything needed for a point-of-care decision in under a minute.
-
2Formulations & Class Comparison IR vs. ER, prodrug considerations, single-isomer vs. mixed salts, formulation-specific safety profiles, and within-class trade-offs.
-
3Pharmacokinetics & Placental Transfer Maternal PK changes by trimester, placental transfer ratios, fetal exposure estimates, and dose-adjustment principles.
-
4FDA Label & Verbatim Regulatory Language The exact FDA pregnancy language, animal reproductive toxicity findings, and how to interpret post-PLLR labeling for shared decision-making.
-
5Teratogenicity, Obstetric & Neonatal Outcomes Major malformation risk, preeclampsia/SGA/preterm birth signals, NAS, and the largest available pregnancy cohorts for each medication.
-
6Clinical Decision Algorithm & "Safe-Use" Protocol Step-by-step decision tree for continue/switch/discontinue, dose optimization, monitoring schedule, and trimester-specific actions.
-
7Drug Interactions & Anesthesia Considerations Antacid/PPI interactions for amphetamines, halogenated agent considerations for stimulants, neuraxial considerations for alpha-2 agonists, CYP2D6 for atomoxetine, CYP1A2 for viloxazine.
-
8Special Populations & Red Flags SUD history, cardiac comorbidities, comorbid mood/anxiety disorders, preterm delivery considerations, and stop criteria for each class.
-
9Clinical Pearls, FAQ, EMR Templates & Patient Scripts Ready-to-paste shared decision-making language, EMR documentation templates that cover FDA label disclosure, and verbatim patient counseling scripts for the clinic.
Six chapters covering ADHD pharmacotherapy during lactation — with measured human milk PK data, FDA label review, infant outcome evidence, and a unified decision framework for the breastfeeding mother on ADHD treatment. Includes the landmark Yamada 2025 atomoxetine study (lowest measured RID of any ADHD medication) and the January 2025 Qelbree label update (the first ADHD treatment to fulfill the FDA's 2019 Clinical Lactation Studies post-marketing requirement).
- Amphetamine & Breastfeeding
- Methylphenidate & Breastfeeding
- Alpha-2 Adrenergic Agonists & Breastfeeding
- Atomoxetine & Breastfeeding
- Viloxazine & Breastfeeding
- Cross-Class Synthesis — Clinical Decision-Making
Academy Membership includes this entire course (both sections), the full perinatal psychopharmacology library (antidepressants, antipsychotics, mood stabilizers, ADHD), CME-eligible chapters, and access to every new course as it launches. Cancel anytime.
Responses